DEXILANT SOLUTAB Rx
Generic Name and Formulations:
Dexlansoprazole 30mg; del-rel orally disintegrating tabs.
Takeda Pharmaceutical Company
Indications for DEXILANT SOLUTAB:
Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). Maintenance of healing of EE and relief of heartburn.
Two 30mg SoluTabs are not interchangeable with one 60mg capsule. Caps: Swallow whole, or sprinkle granules on 1 tablespoon of applesauce and swallow immediately. SoluTabs: Take ≥30mins before meal. Place tab on tongue, allow to disintegrate, and swallow without water. May also swallow whole with water or give via oral syringe or NG tube; see full labeling. EE healing: 60mg cap once daily for up to 8 weeks. Maintenance of healed EE and relief of heartburn: 30mg once daily for up to 6 months in adults or 4 months for ages 12–17. Symptomatic GERD: 30mg once daily for 4 weeks. Moderate hepatic impairment (Child-Pugh Class B) for EE healing: 30mg once day for up to 8 weeks.
<12yrs: not established.
Concomitant rilpivirine-containing products.
Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption/deficiency of Vit. B12. Monitor magnesium levels during prolonged therapy. Increased risk of fundic gland polyps with long-term use (esp. >1yr) or osteoporosis-related fractures (hip, wrist or spine) with long-term (>1yr) and multiple daily dose PPI therapy. Use lowest dose for shortest duration appropriate to condition. Pregnancy. Nursing mothers.
Proton pump inhibitor.
See Contraindications. Avoid concomitant nelfinavir, St. John's Wort, rifampin. May decrease atazanavir levels. May potentiate saquinavir, digoxin, tacrolimus, methotrexate (consider temporary withdrawal of the PPI); monitor. May alter absorption of pH-dependent drugs (eg, iron, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole). Caution with drugs that may cause hypomagnesemia (eg, diuretics); monitor. Monitor warfarin. May cause false (+) results in diagnostic investigations for neuroendocrine tumors; withhold dexlansoprazole ≥14 days prior to CgA level assessment. May cause false (+) urine screening tests for THC; use alternatives. May interfere with secretin stimulation test; withhold dexlansoprazole ≥30 days prior to assessment. SoluTabs: avoid alcohol.
Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, flatulence, headache, nasopharyngitis, oropharyngeal pain; possible C. difficile-associated diarrhea; rare: hypomagnesemia.
Hepatic (CYP2C19, 3A4); 96.1–98.8% protein bound.
Caps—30, 90, 100, 1000; SoluTabs—100
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|